Details of the Drug Reposition

General Information of This Drug (ID: DMY9U56)

• Drug Name: BC-819 (DMY9U56)

Information on Drug Reposition of This Drug

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pancreatic cancer	DISJC981	2C10	Phase 2	[1]
Bladder cancer	DISUHNM0	2C94	Phase 2	[1]

References

• [1] ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.